Prevention of ovarian damage during chemotherapy by
gonadoliberine analogues administration

a 2007

Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration

ŠMARDOVÁ, Lenka, Martin HUSER, Igor CRHA, Zdeněk KRÁL, Pavel VENTRUBA et. al.

Základní údaje

Originální název

Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration

Název česky

Prevence poškození ovariálních funkcí chemoterapií pomocí analog gonadoliberinu.

Autoři

ŠMARDOVÁ, Lenka (203 Česká republika, garant), Martin HUSER (203 Česká republika), Igor CRHA (203 Česká republika), Zdeněk KRÁL (203 Česká republika), Pavel VENTRUBA (203 Česká republika) a Jiří VORLÍČEK (203 Česká republika)

Vydání

Haematologica/Teh Hematology Journal, 2007

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 5.516

Kód RIV

RIV/00216224:14110/07:00019138

Organizační jednotka

Lékařská fakulta

ISSN

UT WoS

000250470800127

Klíčová slova anglicky

Hodgkins lymphoma; gonadoliberine analogues; premature ovarian failure

Štítky

gonadoliberine analogues, Hodgkins lymphoma, premature ovarian failure

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 22. 2. 2010 09:50, MUDr. Lenka Šmardová

Anotace

ORIG CZ

V originále

Background: The risk of POF onset depends mainly on womens age and foliculogenesis status in ovary, chemotherapy (CT) regimen used and cumulative dose of single cytotoxic agents. Aims: Aim of this prospective case-control study is evaluation of gonadoliberine analogues (GnRHa) administration to patients with Hodgkins lymphoma (HL) during chemotherapy and prevention of ovarian damage depending upon CT dose and regimen. Methods: Study group consists of 72 patients in fertile age with HL by curative CT together with GnRHa administration according standardized protocol. Group A received ABVD, group B baseline BEACOPP and ABVD in combination, group C dose escalated BEACOPP regimen. Results: In study group with GnRHa administration during CT there was statistical significantly less cases with POF (38.2 %) in 6 month after end of CT than in control group (73.4 %). After 12 month POF was detected in 48.8 % of cases versus 69.3 % in control group. Summary: Study proved significant reduction of ovarian failure risk in women with HL treated with less aggressive CT regimens.

Česky

Prevence poškození ovariálních funkcí chemoterapií pomocí analog gonadoliberinu.

Návaznosti

NR8469, projekt VaV

Název: Možnosti ochrany reprodukčních funkcí u žen podstupujících chemoterapii pro hematologickou malignitu

Citovat

ŠMARDOVÁ, Lenka, Martin HUSER, Igor CRHA, Zdeněk KRÁL, Pavel VENTRUBA a Jiří VORLÍČEK. Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration. In Haematologica/Teh Hematology Journal. 2007. ISSN 0390-6078.

@proceedings{747096,
   author = {Šmardová, Lenka and Huser, Martin and Crha, Igor and Král, Zdeněk and Ventruba, Pavel and Vorlíček, Jiří},
   booktitle = {Haematologica/Teh Hematology Journal},
   keywords = {Hodgkins lymphoma; gonadoliberine analogues; premature ovarian failure},
   language = {eng},
   title = {Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration},
   year = {2007}
}

TY  - CONF
ID  - 747096
AU  - Šmardová, Lenka - Huser, Martin - Crha, Igor - Král, Zdeněk - Ventruba, Pavel - Vorlíček, Jiří
PY  - 2007
TI  - Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration
KW  - Hodgkins lymphoma
KW  - gonadoliberine analogues
KW  - premature ovarian failure
N2  - Background: The risk of POF onset depends mainly on womens age and foliculogenesis status in ovary, chemotherapy (CT) regimen used and cumulative dose of single cytotoxic agents. Aims: Aim of this prospective case-control study is evaluation of gonadoliberine analogues (GnRHa) administration to patients with Hodgkins lymphoma (HL) during chemotherapy and prevention of ovarian damage depending upon CT dose and regimen. Methods: Study group consists of 72 patients in fertile age with HL by curative CT together with GnRHa administration according standardized protocol. Group A received ABVD, group B baseline BEACOPP and ABVD in combination, group C dose escalated BEACOPP regimen. Results: In study group with GnRHa administration during CT there was statistical significantly less cases with POF (38.2 %) in 6 month after end of CT than in control group (73.4 %). After 12 month POF was detected in 48.8 % of cases versus 69.3 % in control group. Summary: Study proved significant reduction of ovarian failure risk in women with HL treated with less aggressive CT regimens.
ER  -

ŠMARDOVÁ, Lenka, Martin HUSER, Igor CRHA, Zdeněk KRÁL, Pavel VENTRUBA a Jiří VORLÍČEK. Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration. In \textit{Haematologica/Teh Hematology Journal}. 2007. ISSN~0390-6078.

Podrobný výpis o publikaci